Events & Ideas

To be presented at the 84th CPDD Annual Scientific Meeting, June 11-15, 2022.

Use of kratom, a botanical indigenous to Southeast Asia, has increased dramatically in the U.S. since 2006 with products proliferating rapidly. This is noteworthy, as kratom leaves contain bioactive alkaloids of which at least four act as partial, seemingly biased, agonists at mu opioid receptors and with activity at other neurotransmitter receptors. 

Henningfield JE, Huestis MA, Grundmann O, Swogger MT, Prozialeck WC, Garcia-Romeu A, McCurdy CR. This is a collaborative comment of concerned scientists regarding the WHO ECDD report addressing the review status of kratom and its alkaloids. READ OUR COMMENT

Henningfield, J., Barr, M., Wang, D. and Huestis, M. American College of Neuropsychopharmacology, virtual meeting, Poster presented virtually, December 9, 2020.

Singh D, Brown PN, Cinosi E, Corazza O, Henningfield JE, Garcia-Romeu A, McCurdy CR, McMahon LR, Prozialeck WC, Smith KE, Swogger MT,Veltri C, Walsh Z, Grundmann O Frontiers in Psychiatry, 11:574483, 2020   View publication

Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D. The International Journal on Drug Policy 70:70–77, 2019   View publication

Henningfield J.E., Grundmann, O., Babin, J., Laredo, G., and Cone, E.   View PDF

Henningfield JE, Babin J, Boyer EW, Brown P, Garcia-Romeu A, Griffiths RR, Grundmann O, Hemby SE, McCurdy CR, Raffa RB, Swogger MT, Walsh Z November 28, 2018   View PDF

Henningfield JE, Swogger MT, Walsh Z, Kruegel AC, Grundmann O, Garcia-Romeu A, Raffa RB, Griffiths RR, Brown P June 12, 2018 Dear Leader McConnell, Leader Schumer, Speaker Ryan, and Leader Pelosi: We write today to address the U.S. Food and Drug Administration’s (FDA) recommendation to the Drug Enforcement Administration (DEA) to schedule the kratom plant… Read More